Commercialization giant Eversana has bulked up its data and analytics offering with the acquisition of HVH Precision Analytics from Havas Health & You (HH&Y) and Perspecta. The deal adds a range of data-fueled capabilities, including advanced machine learning and patient identification in rare and misdiagnosed disorders, to Eversana’s expanding slate.
The deal comes as somewhat of a surprise, if only because HH&Y leadership had long touted the HVH unit as its “secret weapon.”
Eversana and HH&Y will, however, continue to work together, with details of what the companies characterized as “an exclusive strategic partnership” set to be disclosed within the next few weeks.
“We’re maintaining the relationship with Havas and will expand it,” said Brigham Hyde, president, data and analytics at Eversana. He believes, for instance, that the market access/payer and value communications strengths of Eversana Engage pair well with HH&Y’s expansive offerings.
“Very often we’re the execution arm of the commercialization process,” Hyde explained. “A lot of time, the advice and guidance that Havas creates, we end up executing. Having a tighter tie there made a ton of sense.” An HH&Y spokesperson did not immediately respond to an emailed request for comment.
The deal came together during the pandemic shutdown, with Eversana one of “multiple bidders,” Hyde said. After a host of phone calls and Zoom meetings, Hyde and HVH CEO Steve Costalas sorted many of the remaining details at a socially distanced meal in Princeton, NJ. Costalas will remain with the company, though his title—and those of other HVH leaders—hasn’t been finalized. The HVH brand will be formally merged into Eversana before the end of the year.
Given the broad range of activities in which Eversana engages on behalf of its clients – everything from running copay programs to servicing specialty pharmacies – importing deeper data and analytics expertise is a no-brainer. “At the core, what makes those services run well is data and analytics,” Hyde said. “This is a great building block for what we’re trying to become, as both a prediction-driven business and a digital business.”
HVH Precision Analytics was formally debuted in early 2017 by the predecessor organizations of HH&Y (Havas Health) and Perspecta (Vencore). At the time, then-HVH chief operating officer Jeff Ceitlin noted that the unit’s analytical rigor had been battle-tested, literally, in a different arena. “If [Vencore] can use data and analytics to find bad guys in Afghanistan, they can use it to find [undiagnosed] patients,” he told MM&M.
In the wake of the acquisition, HVH’s 30 or so full-time employees will be integrated into Eversana’s data and analytics unit, while its primary Wayne, PA, office will become the 31st outpost in the Eversana global network. The other three locations listed on HVH’s website – in New York, Boston and Hamilton Township, NJ – are Havas network sites that hosted small HVH teams, according to an Eversana spokesperson. Eversana counts more than 2,700 employees around the globe.
Hyde joined Eversana in April. He arrived from Concerto HealthAI, a data and AI startup focused on oncology.